Diaquitte 2mg capsules

Riik: Suurbritannia

keel: inglise

Allikas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Toimeaine:

Loperamide hydrochloride

Saadav alates:

E M Pharma

ATC kood:

A07DA03

INN (Rahvusvaheline Nimetus):

Loperamide hydrochloride

Annus:

2mg

Ravimvorm:

Oral capsule

Manustamisviis:

Oral

Klass:

No Controlled Drug Status

Retsepti tüüp:

Valid as a prescribable product

Toote kokkuvõte:

BNF: 01040200; GTIN: 5037145000140

Infovoldik

PACKAGE LEAFLET: INFORMATION FOR THE USER
DIAQUITTE 2 MG CAPSULES
LOPERAMIDE HYDROCHLORIDE
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
This medicine is available without prescription. However, you still
need to take Diaquitte Capsules carefully
to get the best results from them.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist have told you.
•
Keep this leaflet. You may need to read it again.
•
Ask your pharmacist if you need more information or advice.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
•
You must talk to a doctor if you do not feel better or if you feel
worse after 24 hours
.
WHAT IS IN THIS LEAFLET:
1.
WHAT DIAQUITTE CAPSULES ARE AND WHAT THEY ARE USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DIAQUITTE CAPSULES
3.
HOW TO TAKE DIAQUITTE CAPSULES
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE DIAQUITTE CAPSULES
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT DIAQUITTE CAPSULES ARE AND WHAT THEY ARE USED FOR
Diaquitte Capsules contain Loperamide, which belongs to a group of
drugs called antidiarrhoeals.
Diaquitte Capsules are used to treat the symptoms of sudden
short-lived (acute) cases of diarrhoea in adults and
children aged 12 years and over.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DIAQUITTE CAPSULES
DO NOT TAKE DIAQUITTE CAPSULES IF YOU:
•
are allergic (hypersensitive) to loperamide or any of the other
ingredients of this medicine (listed in
section 6)
•
have acute dysentery, which is characterised by blood in your stools
and a high temperature
•
have acute ulcerative colitis (inflammation of the large intestine,
accompanied by ulcers)
•
have a bacterial infection of the intestines, such as salmonella
poisoning
•
have an infection of the large intestine following the use of
antibiotics
•
have constipation, or any form of inflammation or blockage of

Toote omadused

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Diarrhoea Relief Capsules
Loperamide 2 mg Capsules
Wilko Diarrhoea Relief Capsules
Diaquitte 2mg Capsules
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 2 mg Loperamide Hydrochloride.
Excipient(s) with known effect:
This product contains lactose monohydrate
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Green and dark grey, size 4 capsules containing a fine white powder.
Printed
'LOP2'.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Loperamide hydrochloride is indicated for the symptomatic treatment of
acute
diarrhoea in adults and children aged 12 years and over.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
For oral administration.
The capsules should be taken with liquid.
Adults and Children 12-17 years
The initial dose is 2 capsules (4 mg) for adults and 1 capsule (2 mg)
for children;
followed by 1 capsule (2 mg) after every subsequent loose stool.
Further investigation into the cause of the diarrhoea should be
considered if there is no
improvement within 24 hours of starting treatment with loperamide
hydrochloride.
The maximum dose is 6 capsules (12 mg) daily for adults and children
aged 12-17 years.
Paediatric Populations
The capsules should not be used in children under 12 years of age.
Elderly
No dose adjustment is required for the elderly.
Patients with Renal Impairment
No dose adjustment is required for patients with renal impairment.
Patients with Hepatic Impairment
Although no pharmacokinetic data are available in patients with
hepatic impairment
loperamide HCl should be used with caution in such patients because of
reduced first
pass metabolism (see Section 4.4).
4.3
CONTRAINDICATIONS
•
Hypersensitivity to the active substance or to any of the excipients
listed in section
6.1.
•
Not to be used in children under 12 years of age.
•
Not for use when inflammatory bowel disease is present.
•
Loperamide HCl should not be used as the primary therapy:
•
in patients with acute dysentery, whi